Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer gene and immunotherapy: recent developments.

P Jantscheff1, R Herrmann, C Rochlitz

  • 1Department of Research/Molecular Cancer Research, Kantonsspital, Basel, Switzerland. jantscheff@ubaclu.unibas.ch

Medical Oncology (Northwood, London, England)
|August 24, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pegylated liposomal doxorubicin (PLD) in daily practice-A single center experience of treatment with PLD in patients with comorbidities and older patients with metastatic breast cancer.

Cancer medicine·2023
Same author

Targeting immunoliposomes to EGFR-positive glioblastoma.

ESMO open·2022
Same author

Focusing on cancer patients' intentions to use psychooncological support: A longitudinal, mixed-methods study.

Psycho-oncology·2018
Same author

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.

European journal of nuclear medicine and molecular imaging·2013
Same author

[Breast cancer - Treatment guidelines and new treatment options in 2012, a medical oncology prospective].

Therapeutische Umschau. Revue therapeutique·2012
Same journal

Nanomedicine-based sensitization and resistance reversal in immunotherapy of clear cell renal cell carcinoma: from tumor microenvironment to precision delivery.

Medical oncology (Northwood, London, England)·2026
Same journal

Expedited regulatory approval pathways for novel oncology drugs.

Medical oncology (Northwood, London, England)·2026
Same journal

Disulfidptosis and its molecular mechanisms in cancer: mechanisms, regulation, and therapeutic potential.

Medical oncology (Northwood, London, England)·2026
Same journal

DC-intrinsic SHP1 restrains central memory CD8⁺ T cell formation via the TCF-1/Wnt/β-Catenin axis.

Medical oncology (Northwood, London, England)·2026
Same journal

Site-specific trastuzumab Fab-DM1 via butelase-1 with ABD fusion for potent HER2-positive tumor control.

Medical oncology (Northwood, London, England)·2026
Same journal

Unraveling the link between genomic instability and tumor immune evasion in oral squamous cell carcinoma: Role of CBMN assay and emerging perspectives.

Medical oncology (Northwood, London, England)·2026
See all related articles

This review covers gene and immunotherapies for human malignant tumors, focusing on gene therapy strategies and cytokine-supported treatments. It critically examines limitations, particularly immune escape mechanisms, hindering cancer treatment effectiveness.

Area of Science:

  • Oncology
  • Immunology
  • Gene Therapy

Background:

  • Human malignant tumors present significant therapeutic challenges.
  • Gene and immunotherapeutic strategies offer novel treatment avenues for cancer.
  • Understanding treatment limitations is crucial for advancing cancer care.

Purpose of the Study:

  • To review current gene and immunotherapeutic approaches for human malignant tumors.
  • To highlight strategies in cancer gene therapy.
  • To discuss recent advancements in cytokine-supported tumor immunotherapy and tumor-specific vaccination.

Main Methods:

  • Literature review of gene and immunotherapeutic strategies for cancer.
  • Analysis of different cancer gene therapy approaches.
  • Examination of cytokine-supported immunotherapy and tumor vaccination.

Related Experiment Videos

Main Results:

  • Gene therapy offers diverse strategies for targeting malignant tumors.
  • Cytokine support and tumor-specific vaccination are emerging immunotherapy options.
  • Immune escape mechanisms represent a significant limitation for these therapies.

Conclusions:

  • Gene and immunotherapies show promise for treating human malignant tumors.
  • Overcoming immune evasion is critical for successful cancer treatment.
  • Further research is needed to enhance the efficacy of these advanced therapies.